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Abstract
Aims/hypothesis Post-translational modifications, such as
isomerisation of native proteins, may create new antigenic
epitopes and play a role in the development of the
autoimmune response. Protein-L-isoaspartate (D-aspartate)
O-methyltransferase (PIMT), encoded by the gene PCMT1,
is an enzyme that recognises and repairs isomerised Asn
and Asp residues in proteins. The aim of this study was to
assess the role of PIMT in the development of type 1
diabetes.
Materials and methods Immunohistochemical analysis of
59 normal human tissues was performed with a monoclonal
PIMT antibody. CGP3466B, which induces expression of
Pcmt1, was tested on MIN6 and INS1 cells, to assess its
effect on Pcmt1 mRNA and PIMT levels (RT-PCR and
western blot) and apoptosis. Forty-five diabetes-prone
BioBreeding (BB) Ottawa Karlsburg (OK) rats were
randomised to receive 0, 14 or 500 μg/kg (denoted as the
control, low-dose and high-dose group, respectively) of
CGP3466B from week 5 to week 20.
Results A high level of PIMT protein was detected in beta
cells. CGP3466B induced a two- to threefold increase in
Pcmt1 mRNA levels and reduced apoptosis by 10% in
MIN6 cells. No significant effect was seen on cytokine-
induced apoptosis or PIMT protein levels in INS1 cells. The
onset of diabetes in the BB/OK rats was significantly delayed
(85.6±9.0 vs 84.3±6.8 vs 106.6±13.5 days, respectively;
p<0.01 for high-dose vs low-dose and control groups), the
severity of the disease was reduced (glucose 22.2±3.2 vs
16.9±2.6 vs 15.8±2.7 mmol; p<0.01 for high- and low-dose
groups vs control group) and residual beta cells were
more frequently identified (43% vs 71% vs 86%; p<0.05
for high-dose vs control group) in the treated animals.
Conclusions/interpretation The results support a role for
post-translational modifications and PIMT in the develop-
ment of type 1 diabetes in the diabetes-prone BB rat, and
perhaps also in humans.
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Introduction
The list of putative autoantigens involved in the develop-
ment of type 1 diabetes is long, but none, maybe not even
insulin, is found in beta cells alone. An explanation for this
apparent paradox is lacking. We proposed that post-
translational protein modifications in the islet trigger
multiple antigen-specific B and T lymphocyte responses
in the initiation phase of the pathogenesis of type 1 diabetes
[1]. Post-translational protein modifications can potentially
create new antigenic epitopes, which may trigger the
production of autoantibodies and T lymphocyte reactivity.
Indeed, many post-translational modifications of target
autoantigens can generate autoimmune responses in human
disease and animal models [2, 3]. Oxidative modifications
of islet GAD, one of the major beta cell autoantigens,
enhance the recognition of this protein by serum antibodies
in humans [4], whereas recognition of an insulin epitope by
CD4+ T cells requires the formation of a disulfide bond
between adjacent cysteine residues [5]. Furthermore, insulin
is prone to in vitro isomerisation [6], i.e. spontaneous
conversion of an Asp or Asn (Asx) residue into an
isoaspartyl residue at susceptible protein sites.
The highly conserved repair enzyme protein-L-isoaspar-
tate (D-aspartate) O-methyltransferase (PIMT), encoded by
the gene PCMT1, recognises isomerised Asx residues and
catalyses the conversion of isoaspartyl to normal aspartyl
residues. Pcmt1 knock-out mice have increased T cell
proliferative responses, and if their bone marrow is
transferred to wild-type mice, the latter develop anti-DNA
autoantibodies [7]. To assess the potential role of post-
translational protein modifications in the development of
type 1 diabetes, as an example, we assessed PIMT
production in normal human tissues and evaluated the
effect of CGP3466B in vitro on PIMT expression and
apoptosis in a murine insulinoma cell line, as well as in
vivo on the development of the disease in the diabetes-
prone BioBreeding (BB) rat. Treatment with the R-(–)-
deprenyl-related compound CGP3466 has been shown to
upregulate Pcmt1 expression in vitro, which, in turn, has
been demonstrated to have a protective effect against
apoptosis [8].
Materials and methods
Human histological studies Fifty-nine tissue samples from
38 organs (multi-tissue array AA7; Superbiochips Labora-
tories, Seoul, Korea) were analysed. A monoclonal PIMT
antibody (Cat. No. P 62620/lot 1; BD Biosciences,
Heidelberg, Germany), EnVision (peroxidase, Cat. No.
K0625; Dako, Glostrup, Denmark), 3,3′-diaminobenzidine
(DAB+; Dako) staining and Erlich’s haematoxylin counter-
staining were used. Control incubation with excess human
PIMT completely abolished antibody binding (Fig. 1b),
supporting specific PIMT staining. For co-localisation with
insulin, the PIMT antibody was detected using mouse
EnVision Fuchsin+ (Dako) or biotin-conjugated donkey
anti-mouse IgG combined with streptavidin conjugated to
gold clusters (NANOGOLD streptavidin; Molecular
Probes, Leiden, the Netherlands) and silver enhancement
(Cat. No. L-24919; Molecular Probes). For insulin detec-
tion, a polyclonal guinea pig anti-insulin antibody (Cat. No.
N1542; Dako), horseradish peroxidase-conjugated donkey
anti-guinea pig IgG (Cat. No. 706-035-148; Jackson
Immunoresearch Laboratories, West Grove, PA, USA) and
DAB+ staining were used (Fig. 1).
Studies in MIN6 cell lines We examined the effect of
CGP3466B on serum-deprived mouse insulinoma (MIN6)
cells. Cells were seeded in 96-well plates in high-glucose
DMEM and 10% FCS. After 24 h, they were washed and
maintained in serum-free medium in the presence of 5, 50,
500 nmol/l or 5 μmol/l CGP3466B or vehicle for 3 days
(replaced daily). Apoptotic cells were detected with the
fluorochrome inhibitor of caspases (FLICA; Chemicon
International, Temecula, CA, USA), and all cells were
counterstained with 4′,6-diamidino-2-phenylindole dihydro-
chloride hydrate (DAPI; Sigma-Aldrich, Steinheim, Ger-
many). Apoptosis was expressed as the percentage of
FLICA-labelled cells. The experiment was repeated twice
and each condition was analysed in quadruplicate.
The expression of Pcmt1 in MIN6 cells was assessed
using real-time RT-PCR. Total RNAwas isolated from cells
cultured in the presence of 0, 50 or 500 nmol/l CGP3466B
for 24 h. RT-PCR was carried out on cDNA using a Light-
Cycler System and SYBR Green I (Roche Diagnostics,
Mannheim, Germany). Transcription levels were normal-
ised to Gapdh and Min51 and total RNA. The experiment
was repeated twice and each condition was analysed in
triplicate.
Studies in INS1 cell lines We examined the effect of
CGP3466B on cytokine-induced apoptosis in rat insuli-
noma (INS1) cells. Cells (passage numbers 37–98) were
seeded in 96-well plates (20,000 per well) and then exposed
(or not) to 150 pg/ml IL-1β (Cat. No. 554577; Becton
Dickinson, Franklin Lakes, NJ, USA) and to three different
concentrations of CGP3466B (50 nmol/l, 5 μmol/l and
200 μmol/l) for 24 h. Apoptosis was quantified using the
fluorescence-based Apo-One Homogeneous Caspase 3/7
Assay (Cat No. G7790; Promega, Madison, WI, USA).
Fluorescence was measured in a Victor Wallac 1,420 multi-
label counter (Perkin Elmer, Boston, MA, USA). The
results are expressed relative to the control conditions (no
IL-1 or CGP3466B exposure). The experiment was
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performed five times and each condition was analysed in
duplicate.
To assess PIMT levels, INS1 cells (passage numbers 37–
98) were seeded in 24-well plates (250,000 per well) and
then exposed to IL-1β and CGP3466B as described above.
The cells were lysed for 30 min on ice and then spun
(12,000 g, 5 min, 4°C), and the protein concentration was
measured in the supernatant fraction by the Bradford
method, following the manufacturer’s instructions (BioRad,
Hercules, CA, USA). Volumes with equivalent protein
content were loaded onto NuPAGE 10% Bis-Tris gels
(Invitrogen, Carlsbad, CA, USA), and the proteins were
separated by electrophoresis and transferred onto nitrocel-
lulose membranes according to the manufacturer’s instruc-
tions. Rabbit anti-(human) PIMT polyclonal antibody
(1:1,000 dilution; Proteintech Group, Chicago, IL, USA)
and mouse anti-β-actin (1:10,000 dilution; Abcam, Cam-
bridge, UK) were used as primary antibodies. The corre-
sponding horseradish peroxidase-conjugated secondary
antibodies (anti-rabbit IgG [1:4,000 dilution; Cell Signaling,
Beverly, MA, USA] and anti-mouse IgG [1:1,000 dilution;
Oncogene, Cambridge, MA, USA]) were then used. Human
SAOS-2 cell lysate was used as a positive control.
The proteins of interest were detected by a chemilumi-
nescence detection system (lumiGLO; Cell Signaling) and
visualised using an LAS3000 imaging system (Fuji Film,
Tokyo, Japan). PIMT levels were quantified and normalised
against β-actin using Multi Gauge software v2.0 (FUJI
Film). The ratio of PIMT:β-actin under control conditions
was arbitrarily set to 1. Values obtained from each
condition were compared using the two-tailed Mann–
Whitney U test. A p value of <0.05 was considered
significant.
Intervention study in diabetes-prone BB Ottawa Karlsburg
rats Forty-five male diabetes-prone BB Ottawa Karlsburg
(OK) rats were randomised to receive three weekly
(Monday, Wednesday, Friday) subcutaneous injections
containing 0.2 ml distilled water (control group) or one of
two doses of CGP3466B (14 μg/kg [low-dose group] or
500 μg/kg [high-dose group]) dissolved in 0.2 ml distilled
water for weeks 5–20. The animals were provided by the
Department of Laboratory Animal Science of the Univer-
sity of Greifswald (Karlsburg, Germany). They were kept
in groups of three in Macrolon cages (Size 3; Ehret,
Emmendingen, Germany), under strict hygienic condi-
tions. The rats had free access to food (Sniff R; Sniff,
Soest, Germany) and water, and were maintained on a 12-h
light–dark cycle (lights on 05.00–17.00 h). They were
cared for according to local guidelines and law, and their
appearance and activity were monitored daily. Body weight
and blood glucose were measured every other week from
week 5 and, after the age of 50 days, animals were inspected
daily and screened for glucosuria twice a week (Diabur-Test
5,000; Boehringer, Mannheim, Germany). Diabetes was
confirmed by blood glucose >11 mmol/l on two consecutive
days, and age of disease onset was defined by the
time glucosuria was detected. Survival time (without
insulin) was defined as time from onset until worsening of
their general condition, with weight loss >10 g/day. At this
Fig. 1 Immunohistochemistry
of normal human pancreas
showing the expression of
PIMT. a Visualisation of PIMT
using DAB+ as the chromogen
(brown staining) in two islets
(arrows). Only a very low level
of staining is seen in cells of the
exocrine pancreas. b PIMT
monoclonal antibody was
blocked with a 100-fold molar
excess of human recombinant
PIMT before being applied to
the tissue section (negative con-
trol). The broken line indicates
the contours of an islet. c Dou-
ble staining of insulin (DAB+,
brown) and PIMT (Fuchsin,
red). d Double staining of insu-
lin (DAB+, brown) and PIMT
(gold label, black dots). Insert
shows the indicated area mag-
nified. PIMT (arrow) is primar-
ily localised to insulin-positive
areas
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point, animals were killed with an overdose of thiopenthal
and their pancreas was removed and examined by a
pathologist unaware of their status and treatment. Each
pancreas was fixed in Bouin’s solution and embedded in
paraffin. Sections (7 μm thick) were stained with haematox-
ylin/eosin or immunohistochemically for insulin by the
alkaline phosphatase, anti-alkaline phosphatase method.
Approximately 35 islets per animal were assessed for the
presence of beta cells.
Results
Distribution of PIMT in human tissue PIMT was produced
in all studied organs, especially in the brain, lymph nodes
and pancreas (data not shown), where it was exclusively
confined to the islets of Langerhans (Fig. 1a). Control
incubation with excess human PIMT completely abolished
antibody binding (Fig. 1b), supporting specific PIMT
staining. Most of the PIMT-positive cells in normal islets
were also insulin-positive (Fig. 1c,d), indicating that high
PIMT levels are present in beta cells.
Effect of CGP3466B on Pcmt1 expression and apoptosis In
serum-deprived MIN6 cells, only the highest dose (5 μmol/l)
of CGP3466B reduced the rate of apoptosis significantly
(10% reduction; p<0.05). CGP3466B treatment increased
levels of Pcmt1 mRNA, as assessed by RT-PCR, by two- to
threefold (data not shown).
In INS1 cells, the two lowest concentrations of
CGP3466B tested (50 nmol/l and 5 μmol/l) produced a
non-significant reduction of IL-1β-induced apoptosis of
15–21%. The highest concentration tested (200 μmol/l) was
toxic to the cells, increasing apoptosis by 325% (p<0.05).
There was no significant effect of IL-1 or CGP3466B
exposure on PIMT levels (data not shown), except for the
complete disappearance of the PIMT band at the highest
CGP3466B concentration.
Intervention study in BB/OK rats The three groups had
similar weights at baseline and after the treatment period
(only non-diabetic rats were included in the latter assess-
ment), and CGP3466B was well tolerated. Overall, the
incidence of diabetes was similar in all three groups, but its
onset was delayed and its severity was reduced in the treated
animals (Table 1, Fig. 2), which showed lower glucose
concentrations at diagnosis, and less weight loss and longer
survival after diagnosis. In the diabetic animals, most islets
displayed heavy lymphocytic infiltration, disrupted archi-
tecture and reduced relative islet volume. Complete loss of
insulin staining was seen in all groups, albeit less frequently
in the high-dose treatment group (Table 1).
Discussion
In the present study, treating BB/OK rats with CGP3466B
led to a delay in the development and a reduction in the
severity of diabetes. CGP3466B is a compound related to
the anti-Parkinson’s drug R-(–)-deprenyl, which has anti-
apoptotic effects on the human neuroblastoma cell line
PUJA [9] and upregulates Pcmt1 expression in rat astroglial
cell cultures [8]. In addition, transfection of mouse cortical
cells with Pcmt1 protects against apoptosis [8]. The effects
Table 1 Main effects of treatment of BB/OK rats with 0 (control), 14























positive cells (n [%])
3 (43) 5 (71) 6 (86)d
Quantitative data are expressed as mean ± SD. a p<0.01 vs control
group; b p<0.01 vs control and low-dose groups; c p<0.05 vs control
and low-dose groups; d p=0.02 vs control group
Fig. 2 Disease-free survival (in days) after treatment with placebo
(control group, continuous line), 14 μg/kg CGP3466B (low-dose
group, short broken line) or 500 μg/kg CGP3466B (high-dose group,
long broken line). The y-axis displays the fraction of rats free from the
disease. p<0.05 for high-dose group vs control and low-dose groups
Diabetologia (2007) 50:676–681 679
described in the BB/OK rats could be due to either a direct
effect on apoptosis or an indirect effect mediated by the
induction of Pcmt1. The latter is supported by the increased
transcription of Pcmt1 in MIN6 cells, despite only a
moderate effect on apoptosis at a higher CGP3466B dose
than that which induced Pcmt1 transcription. Furthermore,
in the rat INS1 cells, no significant effect was seen on
apoptosis. Overexpression of Pcmt1 has an anti-apoptotic
effect similar to that seen in response to the overexpression
of Bcl2 [8], which is in concordance with findings
suggesting that isomerisation of anti-apoptotic molecules
may have a negative effect on their function [10]. Repair of
these post-translational modifications by PIMT possibly
mediates the in vivo anti-diabetic effect of CGP3466B. The
fact that a high level of PIMT was detected in beta cells
supports its role in type 1 diabetes. Indeed, in a cellular
model of beta cell maturation, exposure to cytokines led to
a 1.5-fold decrease in Pcmt1 mRNA expression in mature,
but not immature, pre-beta cells [11], suggesting that PIMT
response may be part of the specific phenotype that makes
the beta cell prone to immune-mediated destruction.
Proteomic studies of this model suggested that post-
translational protein modifications may reflect the acquired
sensitivity of the beta cell to cytokines [12]. In fact, major
putative autoantigens are prone to isomerisation: insulin can
undergo this kind of modification in vitro [6], the GAD65
molecule has four Asx-Gly sites, susceptible to isomer-
isation, three of which are located within recognised
epitopes [13, 14] and the IA2 molecule also contains
several susceptible sites (http://www.ncbi.nlm.nih.gov/
accessed 21 October 2005, accession AF007555.1).
In the present series of experiments, PIMT levels were
not affected by exposure of INS cells to IL-1 or CGP3466B.
There could be different explanations for this, such as
regulation of RNA translation by miRNA and the time
frame studied in these experiments. Non-coding RNA is an
increasingly recognised means of regulating gene expres-
sion in mammals and other complex organisms; miRNA
binding sites are located in the 3′ UTR region of mRNA
molecules [15] and PCMT1 contains at least three putative
binding sites (http://www.genome.ucsc.edu, last accessed in
October 2006, NM 005389, May 2004 Build) [16].
Regarding the time scale for gene transcription and protein
translation, we know that PCMT1 mRNA is downregulated
within the first 6 h after INS1 cell exposure to cytokines (C.
Brorsson, unpublished data), and is upregulated after
exposure of MIN6 cells to CGP3466B for 24 h, but it
remains to be determined whether the latter takes place at
an earlier stage or if changes in protein expression occur
much later. The performance of experiments that simulta-
neously assess Pcmt1 mRNA and PIMT protein levels
should provide an answer to this question.
In conclusion, the present study supports a role for post-
translational protein isomerisation and the repair enzyme
PIMT in the development of type 1 diabetes in the diabetes-
prone BB rat. The findings presented may also support our
hypothesis [1] that non-beta cell-specific proteins may
become beta cell-specific and antigenic by post-transla-
tional modifications induced by changes in the islet
microenvironment during the initiation phase of human
type 1 diabetes. However, further studies are needed to
explain the discordance between mRNA and protein levels.
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